These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

61 related items for PubMed ID: 11257208

  • 1. Multisite phosphotyping of the ErbB-2 oncoprotein in human breast cancer.
    Ouyang X, Gulliford T, Huang GC, Harper-Wynne C, Shousha S, Epstein RJ.
    Mol Diagn; 2001 Mar; 6(1):17-25. PubMed ID: 11257208
    [Abstract] [Full Text] [Related]

  • 2. Adjacent carboxyterminal tyrosine phosphorylation events identify functionally distinct ErbB2 receptor subsets: implications for molecular diagnostics.
    Ouyang X, Huang GC, Chantry A, Epstein RJ.
    Exp Cell Res; 1998 Jun 15; 241(2):467-75. PubMed ID: 9637788
    [Abstract] [Full Text] [Related]

  • 3. Prolactin modulates phosphorylation, signaling and trafficking of epidermal growth factor receptor in human T47D breast cancer cells.
    Huang Y, Li X, Jiang J, Frank SJ.
    Oncogene; 2006 Dec 07; 25(58):7565-76. PubMed ID: 16785991
    [Abstract] [Full Text] [Related]

  • 4. Preferential detection of catalytically inactive c-erbB-2 by antibodies to unphosphorylated peptides mimicking receptor tyrosine autophosphorylation sites.
    Epstein RJ.
    Oncogene; 1995 Jul 20; 11(2):315-23. PubMed ID: 7624146
    [Abstract] [Full Text] [Related]

  • 5. Activation state-specific monoclonal antibody detects tyrosine phosphorylated p185neu/erbB-2 in a subset of human breast tumors overexpressing this receptor.
    DiGiovanna MP, Stern DF.
    Cancer Res; 1995 May 01; 55(9):1946-55. PubMed ID: 7728765
    [Abstract] [Full Text] [Related]

  • 6. Angiogenesis and c-erbB-2 (HER2/neu) overexpression status in primary breast cancer patients: an analysis of 158 needle core biopsies.
    Vameşu S.
    Rom J Morphol Embryol; 2007 May 01; 48(2):121-9. PubMed ID: 17641798
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The correlation of c-erbB-2 oncoprotein and established prognostic factors in human breast cancer.
    Sütterlin MW, Haller A, Gassel AM, Peters K, Caffier H, Dietl J.
    Anticancer Res; 2000 May 01; 20(6D):5083-8. PubMed ID: 11326673
    [Abstract] [Full Text] [Related]

  • 11. Phosphorylation/cytoplasmic localization of p21Cip1/WAF1 is associated with HER2/neu overexpression and provides a novel combination predictor for poor prognosis in breast cancer patients.
    Xia W, Chen JS, Zhou X, Sun PR, Lee DF, Liao Y, Zhou BP, Hung MC.
    Clin Cancer Res; 2004 Jun 01; 10(11):3815-24. PubMed ID: 15173090
    [Abstract] [Full Text] [Related]

  • 12. Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors.
    Creighton CJ, Hilger AM, Murthy S, Rae JM, Chinnaiyan AM, El-Ashry D.
    Cancer Res; 2006 Apr 01; 66(7):3903-11. PubMed ID: 16585219
    [Abstract] [Full Text] [Related]

  • 13. p185neu is phosphorylated on tyrosine in human primary breast tumors which overexpress neu/erbB-2.
    Wildenhain Y, Pawson T, Blackstein ME, Andrulis IL.
    Oncogene; 1990 Jun 01; 5(6):879-83. PubMed ID: 1694290
    [Abstract] [Full Text] [Related]

  • 14. GRB-7 facilitates HER-2/Neu-mediated signal transduction and tumor formation.
    Bai T, Luoh SW.
    Carcinogenesis; 2008 Mar 01; 29(3):473-9. PubMed ID: 17916906
    [Abstract] [Full Text] [Related]

  • 15. Decreased expression of cellular prostatic acid phosphatase increases tumorigenicity of human prostate cancer cells.
    Lin MF, Lee MS, Zhou XW, Andressen JC, Meng TC, Johansson SL, West WW, Taylor RJ, Anderson JR, Lin FF.
    J Urol; 2001 Nov 01; 166(5):1943-50. PubMed ID: 11586265
    [Abstract] [Full Text] [Related]

  • 16. Polyclonal antibodies against gp185HER2 peptides: their putative role in the identification of a particular HER2 status in patients with breast cancer.
    Di Modugno F, Buglioni S, Mottolese M, Bello DD, Cascioli S, Chersi A, Santoni A, Nisticò P.
    J Immunother; 2001 Nov 01; 24(3):221-31. PubMed ID: 11394499
    [Abstract] [Full Text] [Related]

  • 17. ErbB2 overexpression in human breast carcinoma is correlated with p21Cip1 up-regulation and tyrosine-15 hyperphosphorylation of p34Cdc2: poor responsiveness to chemotherapy with cyclophoshamide methotrexate, and 5-fluorouracil is associated with Erb2 overexpression and with p21Cip1 overexpression.
    Yang W, Klos KS, Zhou X, Yao J, Yang Y, Smith TL, Shi D, Yu D.
    Cancer; 2003 Sep 15; 98(6):1123-30. PubMed ID: 12973835
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.
    Kim MJ, Ro JY, Ahn SH, Kim HH, Kim SB, Gong G.
    Hum Pathol; 2006 Sep 15; 37(9):1217-26. PubMed ID: 16938528
    [Abstract] [Full Text] [Related]

  • 20. Suppression of LNCaP prostate cancer xenograft tumors by a prostate-specific protein tyrosine phosphatase, prostatic acid phosphatase.
    Igawa T, Lin FF, Rao P, Lin MF.
    Prostate; 2003 Jun 01; 55(4):247-58. PubMed ID: 12712404
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.